Monday, September 19, 2022 7:39:47 AM
Recent PTN News
- Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 05/02/2024 11:30:00 AM
- Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 • PR Newswire (US) • 04/30/2024 11:30:00 AM
- Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 • PR Newswire (US) • 04/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 10:02:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 05:57:44 PM
- Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) • PR Newswire (US) • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:00:22 PM
- Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:17:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:55:16 PM
- Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 • PR Newswire (US) • 02/09/2024 12:30:00 PM
- Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:16:03 PM
- Palatin Announces Closing of $10 Million Registered Direct Offering • PR Newswire (US) • 02/01/2024 09:00:00 PM
- Palatin Announces $10 Million Registered Direct Offering • PR Newswire (US) • 01/30/2024 01:00:00 PM
- Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 • PR Newswire (US) • 01/08/2024 03:33:00 PM
- Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. • Business Wire • 01/03/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 02:00:18 PM
- Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million • PR Newswire (US) • 12/20/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:45:22 PM
- Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American • PR Newswire (US) • 12/18/2023 09:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:29 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM